Haleos Labs Limited (HALEOSLABS)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have no interest in owning a business simply because the price has fallen; I want to understand the engine underneath. Haleos Labs is a small pharmaceutical company, with a market cap of ₹381 crore, trading at ₹1,415. On the positive side, the balance sheet is not troubling: debt is only 0.31 times equity, the Piotroski score is 7 out of 9, and ROCE of 11.78% covers the cost of capital modestly. Yet the quality metrics are just mediocre. ROE is 9.69%, and at 2.24 times book value, Mr. Market is asking me to pay a premium for a business that is not compounding at exceptional rates. The growth picture deserves scrutiny. Sales increased 12.03%, but profit increased 21.02%; that kind of gap usually comes from thinner taxes, better margins, or one-off gains, and it is rarely linear. A PEG of 1.16 is reasonable if the 21% profit growth persists, but that is a big "if" for a firm whose quarterly profit is only ₹7 crore. The dividend yield of 0.12% is almost a rounding error, so the investor is fully dependent on capital gains. Promoter holding of 71.80% is good to see, because aligned owners matter. Still, I cannot call this a wonderful franchise. I need a durable moat, an owner-earnings check, and a better margin of safety than the current P/E of 19.19 gives me. Haleos is an interesting compounder candidate, not a proven Buffett-style buy at this price. I would put it on the watchlist and wait for either stronger earnings quality or a lower price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer